Global Antiviral Drugs Market, Drivers, Restraints, Opportunities, Threats, Trends, Applications, and Growth Forecast to 2029
-
15992
-
May 2023
-
183
-
-
This report was compiled by Trishita Deb Trishita Deb is an experienced market research and consulting professional with over 7 years of expertise across healthcare, consumer goods, and materials, contributing to over 400 healthcare-related reports. Correspondence Team Lead- Healthcare Linkedin | Detailed Market research Methodology Our methodology involves a mix of primary research, including interviews with leading mental health experts, and secondary research from reputable medical journals and databases. View Detailed Methodology Page
-
Quick Navigation
“Antiviral Drugs Market” is an upcoming market research report by MarketResearch.biz. The report covers in-depth details of the evolving trends in the global antiviral drugs market. The data and information in the report are based on inputs from experts and in-depth market analysis within the specific industry and target market.
Antiviral Drugs Market Report covers growth prospects and market landscape over the next 10 years, along with company details about the top 10 players in the target market. The global antiviral drugs market is segmented on the basis of drug class, type, application, region, and country.
The Antiviral Drugs Market was valued at $54.4 billion in 2021 & is projected to reach $9.7 billion by 2029. It is expected to grow at an 3.5% CAGR between 2021 and 2029.
Antiviral drugs are medicines, which are used for treating viral infections such as human immunodeficiency virus (HIV), hepatitis, herpes, and influenza. Antiviral drugs are administered in the form of vaccines. Moreover, antiviral drugs are used for specific viral infections, except for a few, which are effective against a wide range of viruses.
In addition, different investigational drugs for the treatment of human immunodeficiency virus infection are currently in the pipeline.
One of the major factors expected to drive the growth of the antiviral drug market is the increasing infections of HIV. Moreover, the increasing prevalence of respiratory syncytial virus (RSV), influenza, and hepatitis are projected to drive increasing demand for antiviral drugs over the forecast period.
According to WHO, 887,000 deaths happened in 2015 due to hepatitis B and around 257 million patients were living with the disease 2015. Moreover, according to the Centre for Disease Control and Prevention (CDC), approximately 13 million influenza cases were reported in 2019.
High cost involved in drug development, growth in the demand for alternative medicines, including homeopathy and naturopathy, drop in the price of U.S. Medicare, competitive dynamics, increasing awareness about the availability of vaccines, and other preventive measures are projected to restrain the growth of the market over the forecast period.
Growth Opportunities in the emerging economies of Asia-Pacific and Latin America, Middle East & Africa (LAMEA) regions and the development of broad-spectrum antibiotics are projected to create growth opportunities for key players in the market over the forecast period.
By Drug Class:
Among the drug class segments, the reverse transcriptase inhibitors segment currently accounts for the highest revenue share and is projected to maintain its dominance over the next five years. This can be attributed to its effectiveness in preventing or slowing down viral infections.
By Type:
Among the type segments, the branded segment is projected to maintain dominance in terms of revenue share over the generic segment over the forecast period. This can be attributed to the belief among people that branded medicines are safer than generic medicines.
A generic medicine is also projected to register significant growth in terms of revenue share, which is attributed to the patent expiry of different branded products and increasing adoption in developing countries.
Moreover, a number of key players such as Aurobindo Pharma, Cipla Inc., and Dr. Reddy’s Laboratories Ltd. are focused on producing generic medicines at an affordable rate.
By Application:
The hepatitis segment among the application segments is projected to account for a comparatively higher revenue share over the forecast period.
This can be attributed to the increasing availability of antiviral drugs for treating hepatitis such as tenofovir, entecavir, telbivudine, lamivudine, and adefovir. In addition, increasing incidences of hepatitis is another factor projected to drive the growth of the segment. The HIV segment is projected to be the fastest-growing segment due to the increasing prevalence of HIV.
The antiviral drugs market in North America is expected to dominate the market in terms of revenue share over the forecast period. This growth of the market in the region can be attributed to the availability of sophisticated healthcare infrastructure and the presence of key players in the region.
By Drug Class:
- DNA Polymerase Inhibitors
- Reverse Transcriptase Inhibitors
- Protease Inhibitors
- Neuraminidase Inhibitors
- Others
By Type:
- Branded
- Generic
By Application:
- HIV
- Hepatitis
- Herpes
- Influenza
- Others
By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Attribute Report Details Market Size Ask For Market Size Growth Rate Ask For Growth Rate Key Companies Ask For Companies Report Coverage Revenue analysis, Competitive landscape, Key company analysis, Market Trends, Key segments, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis and more… Historical Data Period 2015-2020 Base Year 2022 Forecast Period 2022-2031 Region Scope North America, Europe, Asia-Pacific, South America, Middle East & Africa Country Scope United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa Revenue in US$ Mn -
-
- Gilead Sciences
- Hoffmann-La Roche AG
- GlaxoSmithKline plc
- AbbVie
- Merck & Co., Inc.
- Johnson & Johnson Services, Inc.
- Bristol-Myers Squibb Company
- Cipla Inc.
- Aurobindo Pharma
- Reddy’s Laboratories Ltd
Our Clients
View Our Licence Options
